<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549913</url>
  </required_header>
  <id_info>
    <org_study_id>MSF0106</org_study_id>
    <nct_id>NCT00549913</nct_id>
  </id_info>
  <brief_title>Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)</brief_title>
  <official_title>A Dose-escalation Study to Assess the Feasibility and Safety of 3 Different Doses of NeoFuse When Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion With Instrumentation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, dose escalation clinical study to evaluate the feasibility, safety,&#xD;
      and tolerability of 3 different doses of immunoselected, culture-expanded, nucleated,&#xD;
      allogeneic MPCs (NeoFuse) when combined with MasterGraft Resorbable Ceramic Granules&#xD;
      (Medtronic Sofamor Danek USA, Inc.) compared to autograft in patients requiring posterior&#xD;
      lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage (to be used with&#xD;
      autologous bone graft material) and 1 or 2 level posterolateral lumbar fusion surgery with&#xD;
      instrumentation. The instrumentation used for this study will be the Monarch® 5.50 mm Spine&#xD;
      System (DePuy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single center, randomized, open-label controlled Phase 1b/2a study&#xD;
      designed to evaluate the safety and preliminary efficacy of MPCs combined with MasterGraft&#xD;
      Granules when compared to use of autologous bone graft in the posterolateral fusion site in&#xD;
      subjects requiring interbody fusion in combination with instrumented 1 or 2 level PLF&#xD;
      procedure. All subjects in this study will undergo a 1 or 2-level (2 or 3 vertebrae)&#xD;
      interbody fusion without the use of the investigational product.&#xD;
&#xD;
      In addition to the interbody fusion procedure, subjects will undergo an instrumented&#xD;
      posterolateral fusion. NeoFuse plus MasterGraft Granules at one of three doses or autograft&#xD;
      will be implanted in the posterolateral lumbar fusion site(s) only.&#xD;
&#xD;
      After the screening and surgical visits, each subject will be evaluated clinically and&#xD;
      radiographically within 3 days and 30 days after surgery, and at 3, 6, and 12 months after&#xD;
      surgery.&#xD;
&#xD;
      Subjects will be evaluated at 24 and 36 months after surgery for safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of NeoFuse (allogeneic mesenchymal precursor cells [MPCs]) when combined with MasterGraft Resorbable Ceramic Granules as a carrier for posterolateral lumbar fusion with instrumentation.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the overall fusion success of the use of NeoFuse plus carrier compared to autograft in the same patient</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess CT scan as a pilot measure of fusion for use in the pivotal study</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To provide preliminary data to support dose selection</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Spondylolisthesis</condition>
  <condition>Spinal Stenosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects to receive lowest dose of NeoFuse (MPCs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 subjects standard posterolateral spinal fusion with instrumentation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects to receive middle dose of NeoFuse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 subjects standard posterolateral spinal fusion with instrumentation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects to receive highest dose of NeoFuse</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 subjects with standard posterolateral spinal fusion with instrumentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeoFuse</intervention_name>
    <description>immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <other_name>Spinal Fusion</other_name>
    <other_name>Stem Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>posterolateral spinal fusion with instrumentation</intervention_name>
    <description>autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <other_name>Spinal Fusion</other_name>
    <other_name>Controls</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women ≥ 18 years of age.&#xD;
&#xD;
          2. Have a documented symptomatic diagnosis of DDD at L1-S1 with or without stenosis and&#xD;
             with or without up to and including Grade II degenerative spondylolisthesis.&#xD;
&#xD;
          3. May also have coexistent spinal or foraminal stenosis as confirmed by MRI or CT&#xD;
             evaluation.&#xD;
&#xD;
          4. Must have clinical symptoms of neurogenic claudication.&#xD;
&#xD;
          5. Must have failed 6 months of nonoperative management.&#xD;
&#xD;
          6. Must be a candidate for lumbar interbody fusion in combination with posterolateral&#xD;
             lumbar fusion with the use of autograft from the iliac crest requiring a 1 or 2-level&#xD;
             fusion of adjacent vertebral levels between L1 and S1.&#xD;
&#xD;
          7. Must have a stable screening electrocardiogram (ECG), as determined by the&#xD;
             investigator that would not preclude surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is pregnant or breastfeeding.&#xD;
&#xD;
          2. Has Grade III or greater spondylolisthesis.&#xD;
&#xD;
          3. Has or is undergoing revision of a prior fusion at the involved levels.&#xD;
&#xD;
          4. Has a history of hypersensitivity or anaphylactic reaction to murine or bovine&#xD;
             products, dimethyl sulfoxide (DMSO), or titanium.&#xD;
&#xD;
          5. Has MRI or CT that shows greater than 50% anterior translocation of cranial vertebral&#xD;
             body or greater than 20 degree angular motion of the listhesis segment.&#xD;
&#xD;
          6. Has a history of active malignancy in the last 5 years, other than basal cell&#xD;
             carcinoma.&#xD;
&#xD;
          7. Has osteoporosis as defined by a dual energy x-ray absorptiometry (DXA T) score of ≤&#xD;
             -3.5 or a history of fragility fractures or other significant bone disease&#xD;
             contraindicating the use of spinal instrumentation.&#xD;
&#xD;
             Note: subjects will be screened using the Simple Calculated Osteoporosis Risk&#xD;
             Evaluation (SCORE) osteoporosis questionnaire.&#xD;
&#xD;
          8. Has a history of Paget's disease of the spine, osteomalacia, or any other metabolic&#xD;
             bone disease.&#xD;
&#xD;
          9. Has a history of prior radiotherapy to the involved area.&#xD;
&#xD;
         10. Has received systemic corticosteroids at a dose equivalent to prednisone &gt; 10 mg/day&#xD;
             within 14 days prior to study procedure.&#xD;
&#xD;
         11. Has received systemic nonsteroidal anti-inflammatory drugs (NSAIDS) within 48 hours&#xD;
             prior to study procedure, and unwilling to refrain from NSAIDS for the first 6 months&#xD;
             following the procedure.&#xD;
&#xD;
         12. Has a positive screen for human immunodeficiency virus (HIV) antibodies.&#xD;
&#xD;
         13. Has had treatment with any investigational therapy administered within 6 months before&#xD;
             implantation surgery. .&#xD;
&#xD;
         14. Is the prior recipient of allogeneic stem cell/progenitor cell therapy.&#xD;
&#xD;
         15. Has a body mass index (BMI) &gt; 3.5&#xD;
&#xD;
         16. Has 20% or greater anti-human leukocyte antigen (HLA) antibody titer and/or has&#xD;
             antibody specificities to donor HLA antigens.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna Skerrett, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mesoblast, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mesoblast.com</url>
    <description>The Sponsor's web site</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 24, 2007</study_first_submitted>
  <study_first_submitted_qc>October 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2007</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adjacent vertebral levels between L1 and S1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

